ReviewBioMed research international2017
Increased Cardiovascular Risk in Patients with Adrenal Insufficiency: A Short Review.
Review in BioMed research international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Cortisol in sickle cell disease: a systematic review and meta-analysis.Blood advances · 2025Pooled it
- Observational
- Acute cardiovascular manifestations of hypocortisolism.World journal of emergency medicine · 2026Article
- Insights from GWAS, TWAS, and DEG analysis: CDKN2B-AS1, MAP3K4, and P2RX2-encoded P2X2 receptor identified as potential therapeutic targets for ischemic heart disease in Russian adults and long-living individuals.Frontiers in cardiovascular medicine · 2026Article
- Ignored or underestimated - evaluation and treatment of cardiovascular risk factors in patients with adrenal insufficiency.Endocrine · 2025Article
- Effects of glucocorticoid replacement therapy in patients with pituitary disease: A new perspective for personalized replacement therapy.Reviews in endocrine & metabolic disorders · 2024Review
- Article
- Mortality in patients with adrenal insufficiency: a protocol for a systematic review and meta-analysis.BMJ open · 2024Article
- Glucocorticoid replacement therapy for primary and secondary adrenal insufficiency and their impact on cognition.Frontiers in endocrinology · 2023Review
- Non-invasive assessment of tissue sodium content in patients with primary adrenal insufficiency.European journal of endocrinology · 2022Article
- Article
- Poor quality of life and sleep in patients with adrenal insufficiency-another cause of increased mortality?Irish journal of medical science · 2022Article
- Evaluation of plasma ACTH in the metyrapone test is insufficient for the diagnosis of secondary adrenal insufficiency.Frontiers in endocrinology · 2022Article
- Circadian Variation in Efficacy of Medications.Clinical pharmacology and therapeutics · 2021Review
- Cardiovascular outcome in patients with adrenal insufficiency-a therapeutic dilemma.Endocrine · 2021Article
- Coronary Spastic Angina Induced by Adrenal Insufficiency.Internal medicine (Tokyo, Japan) · 2020Article
- [Modified-release hydrocortisone for glucocorticoid deficiency].Der Internist · 2020Review
- Association of adrenal insufficiency with patient-oriented health-care outcomes in adult medical inpatients.European journal of endocrinology · 2019Article
- DESE: estimating driver tissues by selective expression of genes associated with complex diseases or traits.Genome biology · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) is the most common cause of death in the world. Recent studies have shown an association between adrenal insufficiency (AI) and increased cardiovascular risk (CVR). Patients with AI receive glucocorticoid (GC) replacement therapy which can lead to varying levels of blood cortisol. It was shown that these imbalances in blood cortisol may lead to a higher prevalence of coronary heart disease, major adverse coronary events, and increased mortality. GC substitution is essential in the treatment of AI without which the disease has been shown to be fatal. The most frequently used GC formula for replacement therapy is hydrocortisone (HC). There is no uniform opinion on hydrocortisone replacement therapy. Alternative GC such as prednisolone is also in use. Overreplacement of GC may lead to adverse effects including obesity, high blood pressure, and hyperglycaemia. Outcome may vary between primary and secondary AI mainly due to differences in the renin-angiotensin-aldosterone system (RAAS). Furthermore, decreased blood levels of cortisol may lead to a compensatory secretion of inflammatory mediators such as Interleukin-1 (IL-1), Interleukin-6 (IL-6), and/or tumor-necrosis factor (TNF). Physicians and patients should be properly educated about the increased risk of CVD in patients with AI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.